Australia markets closed
  • ALL ORDS

    7,670.90
    +12.00 (+0.16%)
     
  • ASX 200

    7,394.40
    +8.00 (+0.11%)
     
  • AUD/USD

    0.7372
    -0.0013 (-0.18%)
     
  • OIL

    71.96
    +0.05 (+0.07%)
     
  • GOLD

    1,803.70
    -1.70 (-0.09%)
     
  • BTC-AUD

    43,676.05
    -539.59 (-1.22%)
     
  • CMC Crypto 200

    778.68
    -15.05 (-1.90%)
     
  • AUD/EUR

    0.6263
    -0.0007 (-0.12%)
     
  • AUD/NZD

    1.0554
    -0.0033 (-0.31%)
     
  • NZX 50

    12,736.32
    +15.48 (+0.12%)
     
  • NASDAQ

    15,089.40
    +149.23 (+1.00%)
     
  • FTSE

    7,027.58
    +59.28 (+0.85%)
     
  • Dow Jones

    35,021.98
    +198.63 (+0.57%)
     
  • DAX

    15,669.29
    +154.75 (+1.00%)
     
  • Hang Seng

    27,321.98
    -401.86 (-1.45%)
     
  • NIKKEI 225

    27,548.00
    +159.80 (+0.58%)
     

BTC Health Limited (BTC.AX) $2.5m Capital Raise to Acquire the Distribution Rights to Bronchitol(R) and Aridol(R)

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
  • Oops!
    Something went wrong.
    Please try again later.
BTC health Limited (ASX:BTC)
BTC health Limited (ASX:BTC)

BTC Health Limited (BTC.AX) $2.5m Capital Raise to Acquire the Distribution Rights to Bronchitol(R) and Aridol(R)

Melbourne, Australia, July 5, 2021 - (ABN Newswire) - BTC Health Limited (ASX:BTC) is pleased to announce the receipt of binding firm commitments for a $2.5 million private placement ('Placement') to fund the acquisition of exclusive distribution rights to Bronchitol(R) and Aridol(R) in Australia, New Zealand, Malaysia, Hong Kong and Singapore. The Placement was strongly supported by the Company's existing institutional and professional investors. Taylor Collison Limited acted as Lead Manager to the Placement.

The issue of 35.7 million fully paid ordinary shares ('Shares') is expected to take place on 9 July 2021 at an issue price of $0.07 per Share, which represents a 5.4% discount to BTC health's last closing price of $0.074 on 30 June 2021. The Shares issued under the Placement will rank equally with the existing ordinary shares of BTC health.

Dr. Richard Treagus, Executive Chairman commented "I wish to thank our major shareholders for their strong support for this transaction, as well as our broader growth plans. Bronchitol(R) and Aridol(R) are a good fit for our business and an important step in building a presence in the speciality pharmaceutical segment of the healthcare market. We are fully committed to realising BTC's growth ambitions, and in so doing generating sustainable returns to shareholders within a fully compliant Pooled Development Fund."

To view the presentation, please visit:
https://www.abnnewswire.net/lnk/0H63AI8S



About BTC Health Limited:


BTC Health (ASX:BTC) is a listed entity on the ASX and is a Pooled Development Fund, registered under the Pooled Development Funds Act 1992. It is a high-growth company, focused on making world-class innovative medical products available to patients in Australia and New Zealand.

Contact:

Richard Treagus
Chairman
Ph: +61 417 520 509
E-mail: rtreagus@btchealth.com.au

Sharon Papworth
Company Secretary
Ph: 1800 100 282
E-mail: spapworth@btchealth.com.au

Source:
BTC Health Limited

Copyright (C) 2021 ABN Newswire. All rights reserved.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting